 "Allergopharma's biopharmaceutical production facility")
Merck’s allergy business Allergopharma has opened its new biopharmaceutical production unit in Reinbek, near Hamburg (Germany).
"By this € 42 million investment Merck is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy market place,” said Simon Sturge, chief operating officer at the healthcare business sector of Merck.
Marco Linari, CEO of Allergopharma, added, “From a technology point of view, the new biopharmaceutical production is a quantum leap. It means an increase in supply safety for patients,
